Literature DB >> 1261795

[Ifosfamide in comparison with cyclophosphamide in advanced ovarian carcinomas (author's transl)].

G Teufel, A Pfleiderer.   

Abstract

Ifosfamide or cyclophosphamide was employed in an alternating series in 49 advanced ovarian carcinomas. The two cytostatic drugs were given in single massive doses. In primary inoperable ovarian carcinomas at stage III and IV a partial remission occurred in 8 of 19 cases (42%) after treatment with cyclophosphamide. Ifosfamide produced a partial or complete remission in 9 of 11 cases (82%). However, 3 patients treated by ifosfamide died within 3 weeks after the administration of the first massive dose. Regarding these cases as failures there was a remission in 9 of 14 cases (64%). Cyclophosphamide enabled a secondary radical operation in 7 of 19 (37%), ifosfamide in 6 of 14 cases (43%). The intervals between an exploratory laparotomy and the secondary radical operation were 5 months on the average for the two cytostatic drugs.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1261795

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  7 in total

1.  The effect of age on the pharmacokinetics of ifosfamide.

Authors:  M J Lind; J M Margison; T Cerny; N Thatcher; P M Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

2.  Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.

Authors:  M J Lind; J M Margison; T Cerny; N Thatcher; P M Wilkinson
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Ifosfamide given as a 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results.

Authors:  P H Willemse; M E vd Burg; A vd Gaast; J P Neijt; W W ten Bokkel Huinink; J G Aalders; E G de Vries
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 4.  Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors:  R M Canetta; S K Carter
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

5.  Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.

Authors:  T M Loeffler; F W Weber; T U Hausamen
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 6.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  [Investigations about the incorporation of nucleotide precursors in single cell suspensions of ovarian- and cervix-carcinomas under the influence of cytostatic therapy (author's transl)].

Authors:  G Teufel; A Pfleiderer; O Doerjer; J Weigand
Journal:  Arch Gynakol       Date:  1977-09-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.